Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-6 of 6 for your search:
Drug:
alum adjuvant
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase Ib/IIa Study of Murine Anti-Idiotypic MOAB BEC2 with Alum Adjuvant in Patients with Advanced Melanoma (Summary Last Modified 03/94)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Protocol IDs:
MSKCC-93103A1
, NCI-V93-0338
2.
Phase I/II Study of Human Anti-Idiotypic Monoclonal Antibody Vaccine (4B5) in Patients with Stage III or IV Melanoma at High Risk for Recurrence Following Surgical Resection
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
UAB-9746
, UAB-F980729009, NCI-G99-1644, NCT00004184
3.
Phase I/II Study of Monoclonal Antibody 105AD7 Anti-Idiotype Vaccine and ONYCR1, ONYCR2, and ONYCR3 Allogeneic Adenocarcinoma Cell-Based Vaccines in Patients With Locally Advanced or Metastatic Adenocarcinoma of the Colon or Rectum
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ONYVAX-SGCRO01
, NCI-V00-1599, NCT00007826
4.
Phase II Randomized Study Comparing Immunologic Responses of Stage II and III Colorectal Cancer Patients on Adjuvant Therapy Treated with 3H1 Anti-Idiotype Monoclonal Antibody Mixed with Sargramostim Versus 3H1 Anti-Idiotype Monoclonal Antibody Alum Precipitate Mixed with Sargramostim (Summary Last Modified 01/2000)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UKMC-95GI24CB
, NCI-H97-1184
5.
Phase II Randomized Adjuvant Study of Vaccination With Tyrosinase, gp100, and MART-1 Peptides Emulsified With Montanide ISA-51 With Interleukin-12 and Either Alum Adjuvant or Sargramostim (GM-CSF) in Patients With Resected Stage IIB, IIC, III, or IV Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M011
, LAC-USC-IRB-013030, NCI-5506, NCT00031733, 5506
6.
Phase I Pilot Study of Immunotherapy with Rat Monoclonal Anti-Idiotypic Antibody BR3E4 (Ab2) with Alum as Adjuvant for Surgically Incurable Colorectal Cancer (Summary Last Modified 01/2000)
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
over 18
Sponsor:
NCI
Protocol IDs:
JMC-9309057
, NCI-H96-0001
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute